HK Stock Market Move | TYK MEDICINES-B(02410) has risen by over 6%, TYK-01054 capsules have initiated Phase I/II clinical trials for the treatment of advanced solid tumors.

TYK MEDICINES-B (02410) rose by over 6%, reaching a 4.6% increase at the time of publication, trading at 13.41 Hong Kong dollars, with a trading volume of 20.8814 million Hong Kong dollars. On the news front, data from the Drug Clinical Trial Registration and Information Disclosure Platform shows that a evaluation of the TEAD inhibitor TYK-01054 capsule from Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd. in local advanced or metastatic late-stage solid tumor patients for safety, tolerability, pharmacokinetics, and anti-tumor activity in a phase I/II, open-label, multicenter study has been initiated. The clinical trial registration number is CTR20255003, with the first disclosure date being December 26, 2025. Public information shows that the TYK-01054 capsule is a chemical drug indicated for late-stage solid tumors. Late-stage solid tumors refer to tumors where cancer cells have spread to other parts of the body, with symptoms varying depending on the type of tumor, commonly presenting as pain, fatigue, etc. Diagnosis is based on imaging tests, pathological biopsy, etc.